Seres Therapeutics (FRA:1S9) ROE % Adjusted to Book Value : -29.09% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics ROE % Adjusted to Book Value?

Seres Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -344.13%. Seres Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 11.83. Seres Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -29.09%.

Seres Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Seres Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics ROE % Adjusted to Book Value Chart

Seres Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-11.72

-7.45

-5.86

Negative Equity

Seres Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	Negative Equity	-29.09

Competitive Comparison of Seres Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Seres Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Seres Therapeutics ROE % Adjusted to Book Value Calculation

Seres Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	11.83
	=	Negative Equity

Seres Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-344.13%	/	11.83
	=	-29.09%

Seres Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Seres Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (FRA:1S9) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MCRB:USA 1S9:Germany

Address

101 Cambridgepark Drive, Cambridge, MA, USA, 02140

Website

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Headlines

No Headlines